Rank the most promising cancer treatments
CureMatch provides a scored and ranked listing of the most promising personalized medicine treatment options. The comprehensive analysis considers commonly-used treatments, as well as targeted therapy, immunotherapy, hormone therapy, and newly-approved cancer drugs, both on-label and off-label. These options are presented either alone (monotherapy) or in combinations of up to 4 drugs.

Filter out therapies that are expected to have poor outcomes
Many cancer treatments are ineffective, and can lead to drug resistance, added cost, and side-effects. CureMatch can rank therapies against its databases of genes, pathways, and drug characteristics to predict which therapies are not likely to work.

Input your own combination therapy options
Combination therapy has been used widely to treat other diseases such as HIV/AIDS, and recent studies have shown it to be effective in cancer. However, its adoption has been limited in cancer due to the complexity. CureMatch allows you to see where your own proposed combinations rank alongside other highly ranked options.


The patient receives a solid/liquid biopsy, and the sample is sent to a 3rd party service provider for tumor profiling. CureMatch can input data from most tumor profiling companies, and can analyze most types of biological data (DNA sequencing, protein expression, etc.), or even integrate multiple types of data.

CureMatch uses its software platform to analyze your genetic information and compare it with our large database of information from medical experts, other patients, clinical trials, and published data.

CureMatch generates an analysis which scores and ranks the most promising treatment options.

CureMatch empowers the physician to make the most informed treatment decisions, considering the most advanced personalized treatment options.




CureMatch is the only company to perform the multi-parametric analyses required to analyze millions of combination options.

CureMatch platform incorporates custom curated databases of publications, clinical trials, genes, pathways, and drug characteristics.

CureMatch looks at all of a patient’s mutations together rather than individually, such that it can analyze options that target multiple mutations rather than single drug therapies targeting individual mutations.

CureMatch integration spans all types of biological data

CureMatch is agnostic to tumor profiling company data


Track Record

The CureMatch approach has been used on thousands of patients since its initial development at the UC San Diego Moores Cancer Center and San Diego Supercomputer Center. Some recent Case Studies are provided.


Cross-disciplinary Expertise

The CureMatch approach has been built upon a foundation of discoveries in oncology, genomics, molecular biology, and many other cross-disciplinary fields. Key Publications are provided.



Most cancers harbor a cocktail of genomic alterations or mutations. Personalized medicine has typically focused on targeting what the oncologist considers to be the most important mutation, using a single “targeted” drug.

CureMatch is unique in that it looks at all of a patient’s mutations together rather than individually. This enables drug combination recommendations targeting multiple mutations rather than single drug therapies.

CureMatch also integrates multiple types of biological results (DNA sequencing, protein expression, etc.) into its comprehensive analysis, and considers commonly-used cancer treatments as well all of the latest advances in cancer care, including immunotherapy, targeted therapy, hormone therapy, and newly approved cancer drugs.

The resulting analysis ranks the top 2-, 3-, and 4- drug combinations (out of more than 4.5 million options) that are customized for each individual patient.

The analysis is not a substitute for a physician’s decision, but rather it empowers the physician to make the most informed decision, using the most advanced personalized treatment options. The clear analysis layout and ranking is designed to provide actionable knowledge and insight to the oncologist.